This flow-chart is that used at the RD&E for the management of painful diabetic peripheral neuropathy
Monday, February 23, 2009
Thursday, February 19, 2009
Management of Painful Diabetic Neuropathy
Angus' presentation, which talks about all neuropathy associated with Diabetes Mellitus with a focus on the treatment options available for painful diabetic neuropathy.
Diabetic Neuropathy
View more presentations from PeninsulaEndocrine.
Friday, February 13, 2009
Consultant Interview Questions
Helen went for the consultant post in Poole, and has been kind enough to upload a list of the questions that she was asked.
Consultant Interview Questions for Poole
View more documents from PeninsulaEndocrine.
Thursday, February 5, 2009
RD&E Exenatide Audit.
Pam Bowman, the academic F2 has audited the initial use of exenatide at the RD&E.
Exenatide, the first commercially available GLP-1 analogue, has been mentioned in the latest NICE guidelines for those with a BMI >35, an HbA1c >7.5%, on maximum oral metformin and sulphonylurea, who would otherwise be starting a high-cost medication.
NICE also mention criteria for success: a weight loss >5% at one year and improvement in HbA1c >1%
The audit is limited in scope as not many patients have been on the medication 6 months, let alone one year.
The interesting issues are that we are using it off-licence (i.e in those already on insulin) and that doesn't seem to influence outcome.
Here is the audit. Other peoples thoughts, experiences and comments would be useful... just use the comments link at the bottom of this post.
Exenatide, the first commercially available GLP-1 analogue, has been mentioned in the latest NICE guidelines for those with a BMI >35, an HbA1c >7.5%, on maximum oral metformin and sulphonylurea, who would otherwise be starting a high-cost medication.
NICE also mention criteria for success: a weight loss >5% at one year and improvement in HbA1c >1%
The audit is limited in scope as not many patients have been on the medication 6 months, let alone one year.
The interesting issues are that we are using it off-licence (i.e in those already on insulin) and that doesn't seem to influence outcome.
Here is the audit. Other peoples thoughts, experiences and comments would be useful... just use the comments link at the bottom of this post.
Exenatide Presentation
View more presentations from PeninsulaEndocrine.
Aspirin for Primary Prevention of Cardiovascular Events in Diabetes: Still an Open Question
This JAMA editorial highlights the uncertainty in the use of aspirin in primary prevention for people with diabetes.
Hopefully the Ascend Trial will help to answer this question.
Below, the Exeter Drugs update (Co-authored by KMM) expands on this issue taking a look at the recently published evidence in the POPADAD and JPAD trials:
Hopefully the Ascend Trial will help to answer this question.
Below, the Exeter Drugs update (Co-authored by KMM) expands on this issue taking a look at the recently published evidence in the POPADAD and JPAD trials:
Exeter Drugs Update
View more documents from PeninsulaEndocrine.
Wednesday, February 4, 2009
The DVLA diabetes and driving guidelines.
These are the DVLA guidelines for driving.
The guidelines are downloadable from here
The guidelines are downloadable from here
Diabetes and Driving
View more documents from PeninsulaEndocrine.
Subscribe to:
Posts (Atom)
Use the links above to jump to various parts of the blog.
- Home - will take you back to the presentations
- About Us & Contacts - will take you to information about the registrars in the region
- Events - Will take you to the Registrar timetable and other key information
- Research - will take you to information about publications, abstracts, posters completed by trainees in the region.